title: [Control of enterohemorrhagic Escherichia coli (EHEC) in cattle].
abstract: Cattle are recognized as the major reservoir of STEC and the source of infection for human beings. Until recently, intervention strategies to decrease the contamination of meat products have been focused on the slaughter plant with the application of practices to reduce the contamination and proliferation of STEC. This has now changed following the development of intervention strategies in the farm. This could be one of the most important points of intervention to lower the incidence of human infection. Vaccines, probiotics, bacteriophages, and changes in production practices may be useful as strategies to control EHEC in the cattle. The application of such intervention measures could be difficult due to the fact that this zoonotic agent rarely causes disease in bovines. The HUS is endemic in Argentina, and the factors leading to this epidemiological situation remain unknown. However, intervention strategies undoubtedly will contribute to reduce the incidence of this zoonosis.
authors.affiliation: Instituto de Patobiología, Centro de Investigación en Ciencias Veterinarias y Agronómicas, Instituto Nacional de Tecnología Agropecuaria (INTA). CC 25, 1712 Castelar, Prov. Buenos Aires, Argentina. emercado@cicv.inta.gov.ar
authors.forename: Elsa C
authors.initials: EC
authors.lastname: Mercado
mesh_terms: D000818:Animals; D001426:Bacterial Proteins / Q000378:metabolism; D001435:Bacteriophages / Q000276:immunology; D002417:Cattle; D004197:Disease Reservoirs / Q000382:microbiology*; D004927:Escherichia coli Infections / Q000276:immunology / Q000517:prevention & control*; D019453:Escherichia coli O157 / Q000472:pathogenicity* / Q000821:virology; D029968:Escherichia coli Proteins / Q000235:genetics / Q000627:therapeutic use; D022361:Escherichia coli Vaccines / Q000627:therapeutic use; D006463:Hemolytic-Uremic Syndrome / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007779:Lactobacillus acidophilus; D010750:Phosphoproteins / Q000235:genetics / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D022621:Shiga Toxin / Q000096:biosynthesis / Q000276:immunology; D014774:Virulence
chemical_list: D001426:Bacterial Proteins; D029968:Escherichia coli Proteins; D022361:Escherichia coli Vaccines; C457340:LEE protein, E coli; D010750:Phosphoproteins; D022621:Shiga Toxin